8-K: KALA BIO Faces Foreclosure, Layoffs, and Nasdaq Delisting

KALA BIO, Inc. announced its secured lender, Oxford Finance LLC, has initiated foreclosure on all assets, swept cash, terminated most employees, and expects delisting from Nasdaq.

Summary

• KALA BIO, Inc. is undergoing foreclosure proceedings initiated by its secured lender, Oxford Finance LLC.
• Oxford Finance LLC declared an event of default on September 29, 2025, making all obligations immediately due and payable under the Loan and Security Agreement.
• On October 18, 2025, Oxford Finance LLC informed the company of its intent to foreclose on all remaining assets and swept substantially all cash resources from its bank accounts.
• The company's Board terminated all remaining employees not deemed necessary by Oxford for the foreclosure process on October 19, 2025.
• Todd Bazemore, President and Chief Executive Officer, was terminated without cause on October 19, 2025, but will continue to serve as a director and principal executive officer.
• After applying the swept cash, Oxford Finance LLC is still owed approximately $9.6 million by the company.
• The company does not expect any distributions to stockholders or unsecured creditors following the foreclosure and potential dissolution.
• KALA BIO anticipates its common stock will be delisted from The Nasdaq Capital Market.
• The company does not expect to be able to continue filing reports with the SEC, including its Quarterly Report on Form 10-Q for the period ended September 30, 2025, and the Annual Report on Form 10-K for the fiscal year ending December 31, 2025.

Sentiment

Score: 1

Explanation: The filing details a complete financial collapse, including lender foreclosure, asset seizure, mass layoffs, CEO termination, anticipated delisting, and no expected recovery for shareholders or unsecured creditors. This represents the most severe negative outcome for a public company.

Negatives

• Secured lender, Oxford Finance LLC, declared an event of default, making all obligations immediately due and payable.
• Oxford Finance LLC initiated foreclosure on all remaining company assets.
• Substantially all of the company's cash resources were swept by Oxford Finance LLC.
• All remaining employees, except those necessary for foreclosure, were terminated.
• President and CEO, Todd Bazemore, was terminated without cause.
• Oxford Finance LLC is still owed approximately $9.6 million after the cash sweep.
• The company does not expect any distributions to stockholders or unsecured creditors.
• Anticipates delisting from The Nasdaq Capital Market.
• Does not expect to be able to continue filing reports with the SEC.

Risks

• Uncertainty regarding the company's ability to continue operations.
• Uncertainty as to the result and timing of the Oxford foreclosure process.
• Risk that actual results may differ materially and adversely from forward-looking statements due to various factors.
• Inability to comply with SEC reporting obligations.
• Inability to maintain the listing of common stock on The Nasdaq Capital Market.
• Likelihood that unsecured creditors and stockholders will receive no distribution or payments from the company.

Future Outlook

The company does not expect to be able to continue filing reports with the SEC, including its Quarterly Report on Form 10-Q for the period ended September 30, 2025, and the Annual Report on Form 10-K for the fiscal year ending December 31, 2025. It also expects its common stock to be delisted from The Nasdaq Capital Market. There is no expectation of distributions to stockholders or unsecured creditors unless foreclosure proceeds exceed the remaining secured debt.

Management Comments

• The Company does not believe that any distributions to stockholders or unsecured creditors will be available following Oxfords foreclosure and in connection with any dissolution of the Company.
• The Company does not expect to be able to continue to file reports with Securities and Exchange Commission.
• The Company also expects that its common stock will be delisted from The Nasdaq Capital Market.

Industry Context

This announcement reflects a severe financial distress scenario for a biotechnology company, highlighting the significant capital requirements and inherent risks in drug development. The cessation of development for KPI-012 and the mesenchymal stem cell secretome platform, followed by lender foreclosure, indicates a failure to secure sufficient funding or achieve viable commercialization, a common challenge in the highly competitive and capital-intensive biotech sector. The inability to continue operations and SEC filings suggests a complete breakdown of the business model, contrasting with companies that successfully navigate clinical trials and secure partnerships or market approvals.

Comparison to Industry Standards

• The company's situation, leading to foreclosure and anticipated delisting, falls significantly below industry standards for operational continuity and financial stability.
• Successful biotech companies typically demonstrate robust funding strategies, positive clinical trial outcomes, and clear pathways to commercialization or strategic partnerships.
• For instance, companies like Moderna (MRNA) or BioNTech (BNTX) successfully leveraged their platforms for rapid product development and market entry, securing substantial capital and generating revenue.
• Even smaller biotechs often manage to secure bridge financing or find acquirers before reaching such a critical juncture. KALA BIO's inability to secure alternative financing or restructure its debt, culminating in a lender-initiated foreclosure, indicates a failure to meet even basic operational benchmarks seen across the industry, where companies strive to maintain liquidity and investor confidence.

Management Changes

Legal Proceedings

• Oxford Finance LLC issued a written notice of event of default under the Loan and Security Agreement.

Stakeholder Impact

• Shareholders: Highly negative impact; no distributions are expected, and common stock is anticipated to be delisted, likely resulting in a complete loss of investment.
• Employees: Significant negative impact due to mass terminations, with only minimal payroll expenses for those assisting with foreclosure.
• Creditors (Secured): Oxford Finance LLC is recovering its debt through asset foreclosure and cash sweep, though still owed $9.6 million.
• Creditors (Unsecured): Highly negative impact; no distributions are expected.

Next Steps

• Oxford Finance LLC will proceed with the foreclosure on all of the company's remaining assets.
• Potential dissolution of the company.
• Anticipated delisting of common stock from The Nasdaq Capital Market.
• Cessation of SEC reporting obligations.

Key Dates

Recommendation

The company is facing imminent dissolution due to lender foreclosure, with all cash swept and remaining assets being seized. There is no expectation of any recovery for stockholders or unsecured creditors, and the stock is expected to be delisted. This situation represents a complete loss of value for equity holders, warranting an immediate strong sell recommendation to mitigate any remaining exposure.

Keywords

KALA BIO, KALA, Foreclosure, Default, Nasdaq Delisting, Employee Termination, CEO Termination, Biotechnology, Financial Distress, SEC Filing, Oxford Finance LLC, KPI-012